Guardant Health
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions decreased by 3 in the most recent period (2026/Q4).
- Total institutional ownership fell 0.7 percentage points.
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 100.39% -0.70pp
- Institutions
- 786 -3
- As of
- 2026/Q4 vs. prior period
Holder types
Top holders as of 2026-09-30
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 25 buys · 23 sells
| Name | Role | Stake |
|---|---|---|
| Helmy Eltoukhy | Co-Founder, Co-CEO & Chairman | 1.69% |
| AmirAli Talasaz | Co-Chief Executive Officer | 1.39% |
| Darya Chudova | Chief Technology Officer | 0.06% |
| Craig Eagle | Former Chief Medical Officer | 0.05% |
| Christopher Freeman | Chief Commercial Officer of Oncology | 0.05% |
| Michael Bell | Chief Financial Officer | 0.04% |
| Kumud Kalia | Chief Information Officer | 0.03% |
| John Saia | Chief Legal Officer | 0.03% |
| Vijaya Gadde | Independent Director | 0.02% |
| Terilyn Monroe | Chief Human Resources Officer | 0.02% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-11 | Alex Azar | Independent Director | Derivative Exercise and Retained | +138 | -- |
| 2026-11-08 | Kevin Sayer | Director | Other Derivative Acquisition | +3,149 | -- |
| 2026-11-08 | Robert Parks | Senior VP, Principal Accounting Officer & Chief Accounting Officer | Other Derivative Acquisition | +18,893 | -- |
| 2026-11-01 | Kevin Sayer | Director | Initial Statement of Beneficial | 0 | -- |
| 2026-11-01 | Robert Parks | Senior VP, Principal Accounting Officer & Chief Accounting Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-10-20 | Roberto Mignone | Independent Director | Derivative Exercise and Retained | +264 | -- |
| 2026-10-16 | Manuel Hidalgo Medina | Independent Director | Derivative Exercise and Retained | +232 | -- |
| 2026-10-15 | Musa Tariq | Independent Director | Derivative Exercise and Sale | -116 | $165.88 |
| 2026-10-15 | Musa Tariq | Independent Director | Intent to Sell (Form 144) | -116 | $165.88 |
| 2026-10-14 | Musa Tariq | Independent Director | Derivative Exercise and Retained | +134 | -- |
| 2026-10-13 | Alex Azar | Independent Director | Open Market Disposition | -69 | $159.89 |
| 2026-10-11 | Alex Azar | Independent Director | Derivative Exercise and Retained | +137 | -- |
| 2026-09-30 | Kumud Kalia | Chief Information Officer | Derivative Exercise and Sale | -3,067 | $174.75 |
| 2026-09-30 | Kumud Kalia | Chief Information Officer | Derivative Exercise and Retained | +2,979 | -- |
| 2026-09-30 | Helmy Eltoukhy | Co-Founder, Co-CEO & Chairman | Derivative Exercise and Sale | -18,515 | $174.75–178.36 |
| 2026-09-30 | Helmy Eltoukhy | Co-Founder, Co-CEO & Chairman | Derivative Exercise and Retained | +18,015 | -- |
| 2026-09-30 | Michael Bell | Chief Financial Officer | Derivative Exercise and Sale | -3,914 | $174.75 |
| 2026-09-30 | Michael Bell | Chief Financial Officer | Derivative Exercise and Retained | +3,366 | -- |
| 2026-09-30 | AmirAli Talasaz | Co-Chief Executive Officer | Derivative Exercise and Sale | -18,515 | $174.75–178.36 |
| 2026-09-30 | AmirAli Talasaz | Co-Chief Executive Officer | Derivative Exercise and Retained | +18,015 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:02:17 · For reference only, not investment advice and not tailored to your situation.
Guardant Health discussion 0 comments